End-Stage Renal Disease (ESRD) Market

• The End-Stage Renal Disease Market Size is anticipated to grow with a significant CAGR during the study period (2019-2032).
• Several pharmaceutical and biotech companies are actively engaged in developing therapies for End-Stage Renal Disease, aiming to improve outcomes and quality of life for affected patients globally. Key End-Stage Renal Disease Companies involved in the drug development - Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, and others

DelveInsight's "End-Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease, historical and forecasted epidemiology as well as the End-Stage Renal Disease therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The ESRD market report provides current treatment practices, emerging drugs, End-Stage Renal Disease market share of the individual therapies, current and forecasted End-Stage Renal Disease market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current ESRD treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the End-Stage Renal Disease market.

End-Stage Renal Disease Treatment Market

The DelveInsight’s End-Stage Renal Disease market report gives a thorough understanding of the End-Stage Renal Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

End-Stage Renal Disease Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for End-Stage Renal Disease.

End-Stage Renal Disease Treatment

It covers the details of conventional and current medical therapies available in the End-Stage Renal Disease market for the treatment of the condition. It also provides End-Stage Renal Disease treatment algorithms and guidelines in the United States, Europe, and Japan. End-Stage Renal Disease clinical trials focus on innovative therapies, dialysis improvements, transplant outcomes, and disease progression, aiming to enhance patient survival, quality of life, and treatment efficacy.

End-Stage Renal Disease Epidemiology 

The End-Stage Renal Disease epidemiology section provides insights about the historical and current ESRD patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the End-Stage Renal Disease market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The End-Stage Renal Disease epidemiology covered in the report provides historical as well as forecasted End-Stage Renal Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

• According to the Centers for Disease Control and Prevention (2022), as of December 31, 2018, ~0.7 million patients (785,883) were being treated for end-stage renal disease (ESRD) in the United States, giving a point prevalence of 2,382 per million population; the prevalence of dialysis treatment was 1,685 per million, whereas the prevalence of functioning kidney transplant was 696 per million.
• Gender differences have been documented in the field of nephrology. Women seem to be somewhat protected from developing ESRD. A nationwide survey of ESRD by the Japanese Society for Dialysis Therapy revealed a higher prevalence in men than in women. Further, the mean age at the start of dialysis is lower in men than in women.

Country Wise- End-Stage Renal Disease Epidemiology

The epidemiology segment also provides the End-Stage Renal Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

End-Stage Renal Disease Drug Chapters

The End-Stage Renal Disease drug chapter segment encloses the detailed analysis of ESRD marketed drugs and late-stage (Phase-III and Phase-II) End-Stage Renal Disease pipeline drugs. It also helps to understand the ESRD clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The End-Stage Renal Disease (ESRD) drugs market is expanding due to rising ESRD prevalence, technological advancements, and increasing demand for effective dialysis, transplant therapies, and supportive pharmaceutical treatments worldwide.

End-Stage Renal Disease Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for End-Stage Renal Disease treatment.

End-Stage Renal Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for End-Stage Renal Disease treatment.

• AB002: Aronora

AB002 (E-WE thrombin), is a first-in-class protein C activator enzyme. AB002 has been designed to act in part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme, endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling vital hemostasis.

• MK-2060: Merck 

MK-2060 is a novel inhibitor of Factor XI being investigated for the prevention of thrombosis in patients with end-stage renal disease (ESRD). MK-2060, administered intravenously, is designed to work through a dual mechanism of action both blocking the activation of Factor XI as well as the downstream activity of the activated protein.

End-Stage Renal Disease Market Outlook

The End-Stage Renal Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted End-Stage Renal Disease market trends by analyzing the impact of current End-Stage Renal Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of End-Stage Renal Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated End-Stage Renal Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the ESRD market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the End-Stage Renal Disease market in 7MM.

The United States End-Stage Renal Disease Market Outlook

This section provides the total End-Stage Renal Disease market size and market size by therapies in the United States.

EU-5 Countries End-Stage Renal Disease Market Outlook

The total End-Stage Renal Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan End-Stage Renal Disease Market Outlook

The total End-Stage Renal Disease market size and market size by therapies in Japan is also mentioned.

End-Stage Renal Disease Drugs Uptake

This section focuses on the rate of uptake of the potential End-Stage Renal Disease drugs recently launched in the End-Stage Renal Disease market or expected to get launched in the market during the study period 2019-2032. The analysis covers End-Stage Renal Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.   

End-Stage Renal Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of End-Stage Renal Disease market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

End-Stage Renal Disease Pipeline Development Activities

The End-Stage Renal Disease report provides insights into different End-Stage Renal Disease clinical trials within in Phase II, and Phase III stage. It also analyses End-Stage Renal Disease key players involved in developing targeted therapeutics.

Pipeline Development Activities

The End-Stage Renal Disease pipeline report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for End-Stage Renal Disease emerging therapies.

Reimbursement Scenario in End-Stage Renal Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current End-Stage Renal Disease market trends, we take KOLs and SMEs ' opinion working in the End-Stage Renal Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or End-Stage Renal Disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the End-Stage Renal Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the End-Stage Renal Disease Market Report

• The report covers the descriptive overview of End-Stage Renal Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the End-Stage Renal Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for End-Stage Renal Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the End-Stage Renal Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global End-Stage Renal Disease market

End-Stage Renal Disease Market Report Highlights

• In the coming years, the End-Stage Renal Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The End-Stage Renal Disease companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Renal Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for End-Stage Renal Disease. The launch of emerging therapies will significantly impact the End-Stage Renal Disease market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for End-Stage Renal Disease
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

End-Stage Renal Disease Market Report Insights

• ESRD Patient Population
• ESRD Therapeutic Approaches
• ESRD Pipeline Analysis
• ESRD Market Size and Trends
• ESRD Market Opportunities
• Impact of upcoming ESRD Therapies

End-Stage Renal Disease Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• ESRD Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• End-Stage Renal Disease Drugs Uptake

End-Stage Renal Disease Market Report Assessment

• Current ESRD Treatment Practices
• ESRD Unmet Needs
• ESRD Pipeline Product Profiles
• ESRD Market Attractiveness
• ESRD Market Drivers
• ESRD Market Barriers

Key Questions Answered In The End-Stage Renal Disease Market Report:

ESRD Market Insights:

• What was the End-Stage Renal Disease drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the End-Stage Renal Disease total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest End-Stage Renal Disease market size during the forecast period (2019-2032)?
• At what CAGR, the End-Stage Renal Disease market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the End-Stage Renal Disease market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the End-Stage Renal Disease market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

ESRD Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the End-Stage Renal Disease?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical End-Stage Renal Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of End-Stage Renal Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to End-Stage Renal Disease?
• Out of all 7MM countries, which country would have the highest prevalent population of End-Stage Renal Disease during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current ESRD Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the End-Stage Renal Disease treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of End-Stage Renal Disease in the USA, Europe, and Japan?
• What are the End-Stage Renal Disease marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many End-Stage Renal Disease companies are developing therapies for the treatment of End-Stage Renal Disease?
• How many therapies are in-development by each company for End-Stage Renal Disease treatment?
• How many are emerging therapies in mid-stage, and late stage of development for End-Stage Renal Disease treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the End-Stage Renal Disease therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for End-Stage Renal Disease and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for End-Stage Renal Disease?
• What are the global historical and forecasted market of End-Stage Renal Disease?

Reasons to buy End-Stage Renal Disease Market Forecast Report

• The report will help in developing business strategies by understanding trends shaping and driving the End-Stage Renal Disease market
• To understand the future market competition in the End-Stage Renal Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for End-Stage Renal Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for End-Stage Renal Disease market
• To understand the future market competition in the End-Stage Renal Disease market